Raymond James initiated coverage of Omega Therapeutics with an Outperform rating and $12 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics Appoints New Chief Business Officer
- Omega Therapeutics To Participate In Two Upcoming Investor Conferences
- Omega Therapeutics appoints Certel as Chief Business Officer
- Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
- Omega Therapeutics presents new preclinical data at ASGCT 2024